Why "muscle-sparing" is a marketing term and not a measurement
The rule that a quarter of weight lost is lean tissue has been in textbooks for decades and does not survive close reading.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 117 of 170 of this archive, newest first.
The rule that a quarter of weight lost is lean tissue has been in textbooks for decades and does not survive close reading.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
The variance around the mean regain trajectory is large and unexplained, exactly as it is for the weight loss.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
Receptor pharmacology explains more of the clinical picture than the dose does — and almost none of it appears in the material patients are given.
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
Reported from the sessions, and from the two hours afterwards.
The document is four pages. Three of them are about dates.
Head-to-head data exists for some of these comparisons and not for others. This piece says which.
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
The document is four pages. Three of them are about dates.
The observation that closes a facility is rarely the dramatic one.
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The document is four pages. Three of them are about dates.
Reported from the sessions, and from the two hours afterwards.
Trial discontinuation figures are a floor, not an estimate: trial populations are supported in ways ordinary patients are not.
Every step between the laboratory report and the product page removes information, and the badge is the last step.
A flag is a probability statement about a population. It is not a statement about the person holding the printout.
The evidence base is thin and the document says so, which is to its credit.